A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome
ClinicalTrials.gov ID NCT07503444 · A Phase 3 Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study With Open-Label Extension to Evaluate the Efficacy And Safety of Fenfluramine Hydrochloride in Study Participants With Rett Syndrome
At a glance
- Status
- Recruiting
- Condition
- Rett Syndrome
- Phase
- Phase 3
- Ages
- 5 Years to 35 Years
- Sex
- All
- Healthy volunteers
- Not accepted
- What is being studied
- fenfluramine hydrochloride (drug); Placebo (other)
- Sponsor
- UCB BIOSCIENCES, Inc.
- Target enrollment
- 200 participants
- Study sites
- 46 open in Arkansas, Belgium, China, Florida, France, Georgia, Germany, Hungary, Israel, Italy, Japan, Pennsylvania, Poland, Spain, Texas, United Kingdom, Washington
- Start date
- 2026-07-14
- Primary completion
- 2029-02-06
Common questions
Is NCT07503444 still recruiting?
ClinicalTrials.gov lists this trial as recruiting (checked 22 November 2026). It has 46 open or upcoming sites.
Who can take part in NCT07503444?
The record lists people aged 5 to 35 years with rett syndrome. The study team decides who is eligible, and the full criteria are on this page and in the official record.
Where is NCT07503444 running?
46 sites in Arkansas, Belgium, China, Florida, France, Georgia, Germany, Hungary, Israel, Italy, Japan, Pennsylvania, Poland, Spain, Texas, United Kingdom, Washington, according to ClinicalTrials.gov.
What is being studied in NCT07503444?
It is a Phase 3 trial. The record lists these interventions: fenfluramine hydrochloride and Placebo. The sponsor is UCB BIOSCIENCES, Inc.
How many people will NCT07503444 enroll?
The record gives a target of 200 participants.
How do I sign up for NCT07503444?
Contact the study team listed in the official ClinicalTrials.gov record.
About this trial
From the ClinicalTrials.gov record.
The purpose of this study is to investigate the efficacy of fenfluramine hydrochloride (HCl) versus placebo in study participants with Rett syndrome (RTT).
Where it's running
| Site | City | State | Status |
|---|---|---|---|
| Ep0247 21010 | Little Rock | Arkansas | Recruiting |
| Ep0247 21009 | Miami | Florida | Recruiting |
| Ep0247 21011 | Orlando | Florida | Recruiting |
| Ep0247 21007 | Atlanta | Georgia | Recruiting |
| Ep0247 21003 | Philadelphia | Pennsylvania | Recruiting |
| Ep0247 21005 | Houston | Texas | Recruiting |
| Ep0247 21013 | Irving | Texas | Recruiting |
| Ep0247 21004 | Seattle | Washington | Recruiting |
| Ep0247 11001 | Brussels | Belgium | Recruiting |
| Ep0247 11002 | Edegem | Belgium | Recruiting |
| Ep0247 42001 | Beijing | China | Recruiting |
| Ep0247 42009 | Shanghai | China | Recruiting |
| Ep0247 12005 | Brest | France | Recruiting |
| Ep0247 12003 | Bron | France | Recruiting |
| Ep0247 12004 | Marseille | France | Recruiting |
| Ep0247 12001 | Paris | France | Recruiting |
| Ep0247 12006 | Paris | France | Recruiting |
| Ep0247 13001 | Tbilisi | Georgia | Recruiting |
| Ep0247 13002 | Tbilisi | Georgia | Recruiting |
| Ep0247 14001 | Vogtareuth | Germany | Recruiting |
| Ep0247 15001 | Budapest | Hungary | Recruiting |
| Ep0247 15002 | Debrecen | Hungary | Recruiting |
| Ep0247 16001 | Ramat Gan | Israel | Recruiting |
| Ep0247 17007 | Florence | Italy | Recruiting |
| Ep0247 17003 | Genova | Italy | Recruiting |
| Ep0247 17001 | Milan | Italy | Recruiting |
| Ep0247 17008 | Naples | Italy | Recruiting |
| Ep0247 17002 | Pisa | Italy | Recruiting |
| Ep0247 17009 | Roma | Italy | Recruiting |
| Ep0247 17006 | Troina | Italy | Recruiting |
| Ep0247 43005 | Chiyoda-ku | Japan | Recruiting |
| Ep0247 43004 | Kodaira | Japan | Recruiting |
| Ep0247 43001 | Kurume | Japan | Recruiting |
| Ep0247 43006 | Musashimurayama-shi | Japan | Recruiting |
| Ep0247 43002 | Osaka | Japan | Recruiting |
| Ep0247 43003 | Setagaya-ku | Japan | Recruiting |
| Ep0247 19003 | Gdansk | Poland | Recruiting |
| Ep0247 19002 | Krakow | Poland | Recruiting |
| Ep0247 11106 | Barcelona | Spain | Recruiting |
| Ep0247 11101 | Madrid | Spain | Recruiting |
| Ep0247 11105 | Madrid | Spain | Recruiting |
| Ep0247 11103 | Málaga | Spain | Recruiting |
| Ep0247 11102 | Seville | Spain | Recruiting |
| Ep0247 11303 | Manchester | United Kingdom | Recruiting |
| Ep0247 11304 | Nottingham | United Kingdom | Recruiting |
| Ep0247 11305 | Stoke-on-Trent | United Kingdom | Recruiting |
Full eligibility criteria (from the record)
Inclusion Criteria: * Participant has typical or classic Rett Syndrome (RTT) according to the RettSearch Consortium 2010 revised criteria * Participant has a documented disease-causing mutation or deletion in the methyl-CpG-binding protein 2 (MECP2) gene * Participant meets criteria for postregression for at least 6 months prior to Screening, defined as: * No loss or degradation of ambulation (including gait, coordination, or independence of walking/standing); * No loss or degradation of hand function; no loss or degradation of speech (including babbling, words, or previously developed communicative vocalizations); * No loss or degradation of nonverbal communicative or social skills (including eye gaze, using body to indicate communicative intent, or social attentiveness) * Participant has an Rett Syndrome Clinical Severity Scale (RTT-CSS) rating of 10 to 36 (inclusive) * Participant has a Clinical Global Impression-Severity (CGIS) score of ≥4 * Participant has a legal representative capable of providing signed informed consent on behalf of the participant as described in the protocol, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol. * Participant is aged 5 to 35 years of age (inclusive) at the time of first administration of investigational intervention. * Male or female. * Participant has a consistent caregiver who is ≥18 years of age at the Screening Visit. The caregiver needs to be able to complete the caregiver assessments defined for the entire study. Every attempt should be made to have the same evaluator complete the assessments for the duration of the study. Exclusion Criteria: * Participant has a history of lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years. * Participant has clinically significant abnormality in vital signs according to the Investigator * Participant has an exclusionary cardiovascular or cardiopulmonary abnormality based on echocardiogram (ECHO), electrocardiogram (ECG), or physical examination, and is not approved for entry by the central cardiac reader. Exclusionary abnormalities include, but are not limited to: 1. Greater than trace aortic valve regurgitation. 2. Greater than mild mitral valve regurgitation. 3. Possible signs of pulmonary arterial hypertension (PAH) with abnormal pulmonary artery systolic pressure (PASP) or PASP ≥35 mmHg. 4. Evidence of left ventricular dysfunction (systolic or diastolic). 5. Clinically significant structural cardiac abnormality, including but not limited to mitral valve prolapse, atrial or ventricular septal defects, or patent ductus arteriosus with reversal of shunt (right to left shunt). Note: Patent foramen ovale without a reversal of shunt or a bicuspid aortic valve is not considered exclusionary * Participant has a clinically significant medical condition, including chronic obstructive pulmonary disease, interstitial lung disease, portal hypertension, or need for invasive mechanical ventilation (eg, via tracheostomy), or has had clinically relevant symptoms or a clinically significant illness currently or in the 4 weeks prior to the Screening Visit that would negatively impact study participation, collection of study data, or pose a risk to the participant * Participant is taking \>4 concomitant antiseizure medications (ASMs). Rescue medications are not included in the count
Other recruiting trials: Rett syndrome clinical trials
This listing shows only what the public ClinicalTrials.gov record NCT07503444 says, last updated there on 2026-11-17. It was checked against the registry on 22 November 2026. Taking part is voluntary, and the study team decides who is eligible. For the most current details, see the official record.